Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis is a paper indexed in PICO Portal from OpenAlex.
How many citations does Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis have?
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis has 94 citations in the OpenAlex counts PICO Portal stores.
When was Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis published?
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis has 2019 year in the PICO Portal index.
What is the open-access status of Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis?
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis has green oa status in the PICO Portal index.
What is the DOI of Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis?
The DOI for Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis is on the source record.
What is the PMID of Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis?
The PMID for Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis is on the source record.
What is the OpenAlex record for Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis?
The OpenAlex for Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis is on the source record.